The nuclear medicine hub in Indiana will generate research, discovery, and evidence of the safety and efficacy of radiopharmaceuticals at a time when the FDA recently has approved two molecular imaging drugs for prostate cancer.
Researchers intend to use a “genome-first” approach that starts by analyzing the genetic information from the health system’s genomic collection studies. Three key takeaways are noted about this partnership.
Although Genomic Testing Cooperative’s agreement with New Jersey-based Hackensack Meridian Health is in its early stages, what is learned from the unique co-op model agreement will be useful for hospital and health system leaders who are evaluating precision medicine approaches.
Insights into a recently published comprehensive review in Cancer Reports. The review, featuring Icahn School of Medicine at Mount Sinai researchers, discusses the implications of using precision medicine to treat prostate cancer in different populations, particularly African American men.
Ongoing growth in consumer genetic testing pressures hospitals and healthcare networks to educate and prepare their primary care physicians for informed patients…
